Genolution

Genolution Rule of 40

The Rule of 40 of Genolution (225220.KQ) as of Nov 19, 2026 is -60.10 %. In the previous year, Rule of 40 was -159.86 % — a change of -62.40% (higher).

Rule of 40

-60.10 %

YoY

-62.40%

Last updated:

Rule of 40 of Genolution is 2025 -60.10 % . Rule of 40 of Genolution was 2024 -159.86 % . It decreases by -62.40% higher compared to the previous year.

The Genolution Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
34.21 KRW
Jan 1, 2019
29.91 KRW
Jan 1, 2020
2,122.58 KRW
Jan 1, 2021
45.21 KRW
Jan 1, 2022
-8.33 KRW
Jan 1, 2023
-157.72 KRW
Jan 1, 2024
-159.86 KRW
Jan 1, 2025
-60.10 KRW
The Genolution Rule of 40 history
YEARRule of 40YoY
-60.10 %-62.40%
-159.86 %+1.36%
-157.72 %+1,794.09%
-8.33 %-118.42%
45.21 %-97.87%
2,122.58 %+6,995.74%
29.91 %-12.57%
34.21 %-61.28%
88.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Rule of 40 of Genolution is -60.10 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Genolution since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Genolution

All Key Metrics — Genolution